Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts
Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson's disease.On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the consensus of $0.14.
上週五，Amneal Pharmaceuticals Inc（納斯達克：AMRX）報告第三季度調整後每股收益爲0.16美元，低於一年前的0.19美元，超過了預期的0.14美元。
The company reported sales of $702.47 million, up 13% year-over-year, beating the consensus of $696.80 million.
該公司報告的銷售額爲70247萬美元，同比增長13%，超過了69680萬美元的預期。
Generic net revenue increased by 9% to $427.35 million, driven by the strong performance of new product launches and biosimilars.
通用淨營業收入增長了9%，達到42735萬美元，受新產品推出和生物類似物性能強勁的推動。
Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson's disease.
專業淨營業收入增長了19%，達到11564萬美元，得益於神經學和內分泌學中推廣的產品，包括近期推出的用於帕金森病的CREXONt和ONGENTYS。
AvKARE's net revenue increased by 21% to $159.49 million, driven by growth across its distribution and government-label sales channels.
AvKARE的淨營業收入增長了21%，達到15949萬美元，這得益於其分銷和政府標示銷售渠道的增長。
Adjusted EBITDA in the third quarter of 2024 was $158 million, an increase of 2% compared to the third quarter of 2023, reflective of strong revenue performance and higher gross margins, partially offset by a $20 million research and development milestone payment associated with the company's exclusive license of Omalizumab during the third quarter of 2024.
2024年第三季度調整後的EBITDA爲15800萬美元，比2023年第三季度增長2%，這反映了強勁的收入表現和較高的毛利率，部分抵消了2024年第三季度公司獨家許可Omalizumab的研發重要階段付款2000萬美元。
"Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth:
“Q3是一個出色的季度，我們在所有業務領域持續推動強勁的財務業績，並宣佈了三項戰略舉措，以鞏固我們的長期增長：
- We launched CREXONT for the treatment of Parkinson's disease.
- We announced our collaboration with Metsera, Inc. to leverage Amneal's expertise and supply next-generation medicines for obesity and metabolic diseases.
- We expanded our deep pipeline by in-licensing a new high-value biosimilar," said Chirag and Chintu Patel, Co-CEOs.
- 我們推出用於帕金森病治療的CREXONt。”
- 我們宣佈與Metsera, Inc. 合作，利用Amneal的專長爲肥胖和代謝性疾病供應下一代藥物。
- 「我們通過授權許可一種新的高價值生物相似藥物來擴大我們深厚的管線，」 Chirag和Chintu Patel，聯合首席執行官說。
Guidance: Amneal has reaffirmed its 2024 revenue guidance of $2.7 billion—$2.8 billion and adjusted EPS of $0.57-$0.63, versus the consensus of $2.76 billion and $0.60, respectively.
指引：Amneal重申其2024年營業收入指引爲27-28億美元，調整後的每股收益爲0.57-0.63美元，而市場共識分別爲27.6億美元和0.60美元。
The company expects 2024 adjusted EBITDA of $610 million—$630 million, operating cash flow of $280 million—$320 million and capital expenditures of $60 million—$70 million.
該公司預計2024年調整後的EBITDA爲61000萬-63000萬美元，經營性現金流爲28000萬-32000萬美元，資本支出爲6000萬-7000萬美元。
Price Action: At last check on Friday, AMRX stock down up 4.88% to $8.19 during the premarket session.
價格走勢：上週五最後的檢查顯示，在盤前交易時段，AMRX股價下跌4.88%，至8.19美元。
- Asia Markets Mixed, Europe, Crude Oil, Gold, And Dollar Cool Off – Global Markets Today While US Slept
- 亞洲市場波動，歐洲、wti原油、黃金和美元穩中降溫-全球市場今日美國睡覺時
熱門市場機會
熱門討論
熱門討論
